EBS News and Press, Emergent Biosolutions Inc. From 01/04/19

GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to ...

GAITHERSBURG, Md., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration (FDA) for potential emergency use of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant) in the ...

Adamis Pharmaceuticals ( ADMP ) had a punishing 2018 thanks principally to the persistent delays to the commercialization of Symjepi, its FDA approved epinephrine injector. That drag on the share price is set to be alleviated in 2019 as Symjepi makes its long awaited debut in the market at l...

GAITHERSBURG, Md., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax ® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active im...

2018 has been a volatile year for Altimmune ( ALT ) from start to finish. The company experienced mixed results in clinical trials as well as changes management positions. Unfortunately, the share price has taken the brunt of the losses and has gained little from the wins. After a reverse spli...

NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT), I...

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda...

GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quart...

Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov...

Emergent BioSolutions Inc. (EBS) Q3 2018 Results Conference Call November 01, 2018 05:00 PM ET Executives Bob Burrows - Vice President of Investor Relations Dan Abdun Nabi - Chief Executive Officer Bob Kramer - President and Chief Operating Officer Rich Lindahl - Chief Financia...